HER2+ breast cancer constitutes 15–20% of cases, and HER2-targeted therapy includes anti-HER2 antibodies such as trastuzumab and pertuzumab, and small-molecule tyrosine kinase inhibitors such as lapatinib and neratinib. This evidence concerns the gene ERBB2 and breast carcinoma.